Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...

Am J Health Syst Pharm. 2011;68(5):389-398.

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...

Untreated gout places a substantial burden on the global health system, as chronic gout causes tophi formation, chronic joint ...

Sensitivity to change has been reported for all methods except MRI and CT. Conclusion A variety of methods of tophus assessment have been described for use in clinical trials of chronic gout. Physical ...

Tophi are firm, painless yellow lesions that form in and around the joints in people with advanced gout. They have a uric acid (monosodium urate) core, and the skin that covers them can become ...

The Biden administration is once again trumpeting the Medicare Prescription Drug Inflation Rebate Program to prove to voters ...

It’s a common ailment for those with lavish tastes—and for the convivial. But it really can strike anyone. But good news for people affected by gout, or at least those ...

Rheumatic diseases make up a collection of arthritis subtypes, but also include fibromyalgia, Sjogren's syndrome, and more.

Gout affects about one in 40 people in the UK and is a form of inflammatory arthritis that causes severe pain and swelling in the joints. The first symptom is often discomfort in the big toe.